Cargando...
Phase 1 Study of XL119, a Rebeccamycin Analog, in Patients With Refractory Hematologic Malignancies
BACKGROUND: XL119 is a water-soluble derivative of rebeccamycin with dose-dependent myelosuppression as dose-limiting toxicity in phase 1 studies of solid tumors. A phase 1 study was conducted to determine the maximum tolerated dose and toxicities of XL119 in patients with advanced myelodysplastic s...
Guardado en:
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
2008
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4126069/ https://ncbi.nlm.nih.gov/pubmed/18473351 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.23559 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|